






Express Mail No. EU 821 024 242 US
Date of Deposit: January 13, 2003

COPY

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/918,589
	Filing Date	July 30, 2001
	First Named Inventor	Cale H. Halbleib
	Group Art Unit	1632
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	PV/17 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
<i>[Signature]</i>	A1	6,218,128	04/17/2001	Allergan Sales			
<i>[Signature]</i>	A2	4,045,420	08/30/1977	Syva Company			29-May-1973
<i>[Signature]</i>	A3	4,331,808	05/25/1982	Miles Laboratories, Inc.			05-Oct-1982
<i>[Signature]</i>	A4	4,420,568	13-Dec-1983	Abbott Laboratories			30-Nov-1981
<i>[Signature]</i>	A5	4,585,862	29-Apr-1986	Abbott Laboratories			08-Feb-1984
<i>[Signature]</i>	A6	4,668,640	26-May-1987	Abbott Laboratories			02-May-1985
<i>[Signature]</i>	A7	5,573,904	12-Nov-1996	Abbott Laboratories			22-May-1995
<i>[Signature]</i>	A8	5,097,097	17-Mar-1992	Abbott Laboratories			30-Jun-1989
<i>[Signature]</i>	A9	5,492,841	20-Feb-1996	E. I. Du Pont de Nemours and Company			18-Feb-1994
<i>[Signature]</i>	A10	5,804,395	08-Sep-1998	The U.S. of America as represented by the Secretary of the Navy			01-Dec-1995


FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1		WO 01/73434	Allergan Sales, Inc.		
	B2		WO 99/18124	Merck & Co., Inc.		
	B3		WO 99/27365	Tularik, Inc.		
	B4		EP 0 672 191 B	PanVera Corporation		
	B5		WO 98/05962	PanVera Corporation		

OTHER NON-PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
<i>[Signature]</i>	C1	Fernandes, P.B., "Technological advances in high-throughput screening," <i>Curr. Opin. Chem. Biol.</i> , 2(5):597-603 (1998).					
<i>[Signature]</i>	C2	Silverman, L., et al., "New assay technologies for high-throughput screening," <i>Curr. Opin. Chem. Biol.</i> , 2(3):397-403 (1998).					
<i>[Signature]</i>	C3	Sittampalam, G.S., et al., "High-throughput screening: advances in assay technologies," <i>Curr. Opin. Chem. Biol.</i> , 1(3):384-391 (1997).					
<i>[Signature]</i>	C4	Lee, P. H. and Bevis, D. J., "Development of a homogeneous high throughput fluorescence polarization assay for G protein-coupled receptor binding," <i>J. Biomol. Screen.</i> , 5(6):415-419 (2000).					
<i>[Signature]</i>	C5	Choi, M. J., et al., "Fluorescence polarization immunoassay of progesterone," <i>Biol. Pharm. Bull.</i> 20(4):309-314 (1997).					
<i>[Signature]</i>	C6	Tota, M. R., et al., "Interaction of [fluorescein-Trp ²⁵] glucagon with the human glucagon receptor expressed in <i>Drosophila</i> Schneider 2 cells," <i>J. Biol. Chem.</i> , 270(44):26466-26472 (1995).					
<i>[Signature]</i>	C7	Casali, E., et al., "Fluorescence investigation of the sex steroid binding protein of rabbit serum: steroid binding and subunit dissociation," <i>Biochem.</i> , 29(40):9334-9343 (1990).					

COPY

OTHER NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
J	C8	Ou, J., et al., "Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR," <i>Proc. Natl. Acad. Sci.</i> , 98(11):6027-6032 (2001).
J	C9	Banks, P., et al., "Impact of a red-shifted dye label for high throughput fluorescence polarization assays for G protein-coupled receptors," <i>J. Biomol. Screen</i> , 5(5):329-334 (2000).
J	C10	Nikov, G. N., et al., "Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex," <i>Environ. Health Perspect.</i> , 108(9):867-872 (2000).
J	C11	Saito, K., et al., "Lack of Significant estrogenic or antiestrogenic activity of pyrethroid insecticides in three <i>in vitro</i> assays based on classic estrogen receptor alpha-mediated mechanisms," <i>Toxicol. Sci.</i> , 57(1):54-60 (2000).
J	C12	Parker, G. J., et al., "Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays," <i>J. Biomol. Screen</i> 5(2):77-88 (2000).
J	C13	Bolger, R., et al., "Rapid screening of environmental chemicals for estrogen receptor binding capacity," <i>Environ. Health Perspect.</i> , 106(9):551-557 (1998).
J	C14	PanVera Corp., Fluorescence Polarization Application Guide, Copyright 1998 Section 5
J	C15	Hwang, K. J., et al., "Donor-acceptor tetrahydrochrysenes, inherently fluorescent high-affinity ligands for the estrogen receptor: binding and fluorescence characteristics and fluorometric assay of receptor," <i>Biochem.</i> , 31(46):11536-11545 (1992).
	C16	Schultz, J. R., et al., "Role of LXRs in control of lipogenesis," <i>Genes & Dev.</i> , 14(22):2831-2838
J	C17	Heery, D. M., et al., "A signature motif in transcriptional co-activators mediates binding to nuclear receptors," <i>Nature</i> , 387(6634):733-736 (1997).
J	C18	Heery, D. M., et al., "Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors," <i>J. Biol. Chem.</i> , 276(9):6693-6702 (2001).
J	C19	Checovich, W. J., et al., "Fluorescence Polarization - a new tool for cell and molecular biology," <i>Nature</i> , 375(6528):254-256 (1995).
J	C20	Ozers, M. S., et al., "Equilibrium Binding of Estrogen Receptor with DNA Using Fluorescence Anisotropy," <i>J. Biol. Chem.</i> , 272(48):30405-30411 (1997).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	3-19-04
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.